title: Targeting paraoxonase-1 in atherosclerosis.
abstract: BACKGROUND
  Paraoxonase-1 (PON1) is a Ca(2+) dependent, high-density lipoprotein-associated lactonase which is capable of retarding/inhibiting low-density lipoprotein (LDL) oxidation. LDL oxidation is believed to be central to the initiation and progression of atherosclerosis, therefore, PON1 is considered to be atheroprotective.
  
  
  METHODS
  Relevant literature on PON1 was identified in PubMed. Here, we discuss the background to research on PON1 in atherosclerosis, the evidence for and against PON1 being atheroprotective, potential mechanisms of this atheroprotection and current knowledge on human PON1 regulation.
  
  
  CONCLUSIONS
  Although current knowledge on PON1 indicates it to be atheroprotective, further clinical and basic studies are warranted to show that PON1 is causally linked to atherosclerosis, how it is atheroprotective and how it is regulated in vivo in humans.
authors.affiliation: AVDA Princip D'Espanya No 152, Miami Playa, Tarragona, Spain. mike.mackness@gmail.com
authors.forename: Mike
authors.initials: M
authors.lastname: Mackness
authors.forename: Bharti
authors.initials: B
authors.lastname: Mackness
mesh_terms: D000818:Animals; D043303:Aryldialkylphosphatase / Q000378:metabolism*; D050197:Atherosclerosis / Q000378:metabolism*; D006801:Humans
chemical_list: D043303:Aryldialkylphosphatase